Prostate Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PRS042 MIFTS: 44	Prostate Disease Categories: Reproductive diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Prostate Disease

MalaCards integrated aliases for Prostate Disease:

Name: Prostate Disease ¹² ¹⁵

Prostatic Diseases ⁴⁴ ⁷³

Prostate Diseases ⁴³

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Diseases of the genitourinary system

Diseases of male genital organs

Disorders of male genital organs in diseases classified elsewhere

Disorders of prostate in diseases classified elsewhere

Other disorders of prostate

Disorder of prostate, unspecified

Other specified disorders of prostate

External Ids:

Disease Ontology ¹² DOID:47

ICD10 ³³ N42.9 N42 N42.8 more

ICD9CM ³⁵ 602.9

MeSH ⁴⁴ D011469

NCIt ⁵⁰ C26865

SNOMED-CT ⁶⁸ 197979000 30281009

UMLS ⁷³ C0033575

Sources

Summaries for Prostate Disease

MedlinePlus : ⁴³ The prostate is a gland in men. It helps make semen, the fluid that contains sperm. The prostate surrounds the tube that carries urine away from the bladder and out of the body. A young man's prostate is about the size of a walnut. It slowly grows larger with age. If it gets too large, it can cause problems. This is very common after age 50. The older men get, the more likely they are to have prostate trouble. Some common problems are Prostatitis - inflammation, usually caused by bacteria Enlarged prostate (BPH), or benign prostatic hyperplasia - a common problem in older men which may cause dribbling after urination or a need to go often, especially at night Prostate cancer - a common cancer that responds best to treatment when detected early NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Prostate Disease, also known as prostatic diseases, is related to prostate cancer and prostatitis, and has symptoms including angina pectoris, tremor and prostatism. An important gene associated with Prostate Disease is PCA3 (Prostate Cancer Associated 3
Diagnostic marker
Dysfunction Pattern: Expression [differentially expressed]). The drugs Lenograstim and Menthol have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and testes.

Wikipedia : ⁷⁶ The prostate (from Ancient Greek προστάτης, prostates, literally \"one who stands before\",... more...

Sources

Related Diseases for Prostate Disease

Diseases related to Prostate Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)

#	Related Disease	Score	Top Affiliating Genes
1	prostate cancer	21.3	CBR3-AS1 CDKN2B-AS1 CTBP1-AS GAS5 H19 IGF2-AS
2	prostatitis	11.0
3	gastric cardia adenocarcinoma	10.2	H19 MEG3
4	astrocytoma	10.2	H19 PCA3 PRNCR1
5	coronary artery anomaly	10.1	CDKN2B-AS1 GAS5 H19 IGF2-AS
6	vulva squamous cell carcinoma	9.8	MALAT1 MEG3
7	aging	9.8
8	wilms tumor 1	9.8	H19 IGF2-AS MEG3
9	pituitary adenoma	9.7	H19 MALAT1 MEG3
10	bladder urothelial carcinoma	9.6	GAS5 MALAT1 MEG3
11	oral squamous cell carcinoma	9.6	H19 MALAT1 MEG3
12	insulin-like growth factor i	9.6
13	prostatic hyperplasia, benign	9.6
14	thyroid cancer	9.6	CDKN2B-AS1 GAS5 H19 MALAT1
15	ovarian epithelial cancer	9.5	H19 MALAT1 MEG3 PCA3
16	liver cirrhosis	9.5	GAS5 MALAT1 MEG3
17	kidney cancer	9.5	GAS5 H19 MALAT1 MEG3
18	breast cancer	9.5
19	myocardial infarction	9.5
20	male infertility	9.5
21	prostatic hypertrophy	9.5
22	rectal disease	9.5
23	papilledema	9.5
24	acromegaly	9.5
25	ischemia	9.5
26	infertility	9.5
27	endotheliitis	9.5
28	thyroid cancer, nonmedullary, 1	9.4	GAS5 H19 MALAT1 MEG3
29	squamous cell carcinoma	9.4	CBR3-AS1 CDKN2B-AS1 H19 MALAT1 PCAT1
30	osteoarthritis	9.4	GAS5 H19 MEG3 PCGEM1
31	gallbladder cancer	9.4	CDKN2B-AS1 H19 MALAT1 MEG3
32	lung cancer susceptibility 3	9.4	GAS5 H19 MALAT1 MEG3
33	myeloma, multiple	9.1	GAS5 H19 MALAT1 MEG3 PCAT1
34	osteogenic sarcoma	9.1	CDKN2B-AS1 H19 MALAT1 MEG3 PCAT1
35	nasopharyngeal carcinoma	9.1	CDKN2B-AS1 GAS5 H19 MALAT1 MEG3
36	melanoma	9.0	CDKN2B-AS1 GAS5 H19 MALAT1 MEG3
37	endometrial cancer	8.9	GAS5 H19 MEG3 PTENP1
38	neuroblastoma	8.9	GAS5 H19 MALAT1 MEG3
39	pancreatic cancer	8.9	CDKN2B-AS1 GAS5 H19 MALAT1 MEG3
40	renal cell carcinoma, nonpapillary	8.8	GAS5 H19 LINC00963 MALAT1 PTENP1
41	glioma	8.8	CBR3-AS1 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3
42	esophageal cancer	8.8	CDKN2B-AS1 GAS5 H19 MALAT1 MEG3 PCAT1
43	ovarian cancer	8.7	CDKN2B-AS1 GAS5 H19 MALAT1 MEG3
44	adamantinoma of long bones	8.4	CDKN2B-AS1 GAS5 H19 MALAT1 MEG3 PCAT1
45	cervical cancer	8.4	CDKN2B-AS1 GAS5 H19 MALAT1 MEG3 PCAT1
46	bladder cancer	8.4	CDKN2B-AS1 GAS5 H19 MALAT1 MEG3 PCAT1
47	malignant glioma	8.2	CDKN2B-AS1 GAS5 H19 LINC00963 MALAT1 MEG3
48	glioblastoma	8.2	GAS5 H19 LINC00963 MALAT1 MEG3 PCAT1
49	lung cancer	8.0	CDKN2B-AS1 GAS5 H19 IGF2-AS MALAT1 MEG3
50	hepatocellular carcinoma	7.8	CBR3-AS1 CDKN2B-AS1 GAS5 H19 IGF2-AS MALAT1

Comorbidity relations with Prostate Disease via Phenotypic Disease Network (PDN):

Prostate Cancer

Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Prostate Disease:

Sources

Symptoms & Phenotypes for Prostate Disease

UMLS symptoms related to Prostate Disease:

angina pectoris, tremor, prostatism, equilibration disorder

Sources

Drugs & Therapeutics for Prostate Disease

Drugs for Prostate Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 824)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Lenograstim

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1

135968-09-1

Menthol

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

2216-51-5

16666

Metformin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

657-24-9

14219 4091

Celecoxib

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

169590-42-5

2662

Bupivacaine

Approved, Investigational

Phase 4,Phase 1,Phase 2,Not Applicable

2180-92-9, 38396-39-3

2474

Doxazosin

Approved

Phase 4,Phase 3,Phase 2,Not Applicable

74191-85-8

3157

Alfuzosin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

81403-80-7

2092

Flutamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

13311-84-7

3397

Finasteride

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

98319-26-7

57363

Iodine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

7553-56-2

807

Prednisolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1

50-24-8

5755

Goserelin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

65807-02-5

47725 5311128

Acetaminophen

Approved

Phase 4,Phase 2,Phase 1

103-90-2

1983

Tamsulosin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

106133-20-4

129211

Dutasteride

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

164656-23-9

152945 6918296

Histamine

Approved, Investigational

Phase 4,Phase 2,Early Phase 1

75614-87-8, 51-45-6

774

Testosterone undecanoate

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

5949-44-0

Ethanol

Approved

Phase 4,Phase 2,Phase 1,Not Applicable

64-17-5

702

Tadalafil

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

171596-29-5

110635

Docetaxel

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

114977-28-5

148124

Testosterone

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

58-22-0

6013

Leuprolide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

53714-56-0

3911 657181

Bicalutamide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

90357-06-5

56069 2375

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4,Not Applicable

437-38-7

3345

Methylprednisolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1

83-43-2

6741

Methyltestosterone

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

58-18-4

6010

Prednisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

53-03-2

5865

Povidone-iodine

Approved

Phase 4,Not Applicable

25655-41-8

Somatostatin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

38916-34-6, 51110-01-1

53481605

Povidone

Approved

Phase 4

9003-39-8

Testosterone enanthate

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

315-37-7

9416

Lidocaine

Approved, Vet_approved

Phase 4,Phase 2,Not Applicable

137-58-6

3676

Denosumab

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

615258-40-7

Ertapenem

Approved, Investigational

Phase 4

153832-46-3

150610

Ciprofloxacin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

85721-33-1

2764

Dihydrotachysterol

Approved

Phase 4,Phase 2

67-96-9

5281010 5311071

Etidronic acid

Approved

Phase 4,Phase 3

7414-83-7, 2809-21-4

3305

Dopamine

Approved

Phase 4,Phase 2

51-61-6, 62-31-7

681

Zoledronic acid

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

118072-93-8

68740

Ofloxacin

Approved

Phase 4,Phase 3,Phase 2

82419-36-1

4583

Aspirin

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable

50-78-2

2244

Ketamine

Approved, Vet_approved

Phase 4

6740-88-1

3821

Gabapentin

Approved, Investigational

Phase 4,Phase 3,Phase 2

60142-96-3

3446

Midazolam

Approved, Illicit

Phase 4,Phase 1,Not Applicable

59467-70-8

4192

Ranitidine

Approved

Phase 4,Phase 2

66357-59-3, 66357-35-5

3001055

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

50-02-2

5743

Prazosin

Approved

Phase 4,Not Applicable

19216-56-9

4893

Metoclopramide

Approved, Investigational

Phase 4

364-62-5

4168

Terazosin

Approved

Phase 4,Not Applicable

63590-64-7

5401

Diphenhydramine

Approved, Investigational

Phase 4,Phase 2,Phase 1

147-24-0, 58-73-1

3100

Interventional clinical trials:

(show top 50) (show all 3953)

#	Name	Status	NCT ID	Phase	Drugs
1	A Prospective Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy	Unknown status	NCT02245334	Phase 4	Povidone-Iodine
2	Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia	Unknown status	NCT02034604	Phase 4	Naftofidil;Tamsulosin
3	Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLight Laser Photoselective Vaporization of the Prostate	Unknown status	NCT02749604	Phase 4
4	Low Dose Bupivacaine Spinal for Trans Uretral Prostatectomy.	Unknown status	NCT01861041	Phase 4	Heavy Bupivacaine;Isobaric Bupivacaine
5	Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)	Unknown status	NCT01301599	Phase 4	combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
6	A Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia	Unknown status	NCT01218672	Phase 4
7	Clinical Study to Assess the Influence of a Saw Palmetto Preparation in Patients With Benign Prostatic Hyperplasia (BPH) and Sexual Dysfunctions	Unknown status	NCT01021267	Phase 4	Saw palmetto berry extract
8	A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart	Unknown status	NCT00690950	Phase 4	Dutasteride
9	Kinetics of the Finasteride Prostate Induced Apoptosis	Unknown status	NCT00130767	Phase 4	finasteride
10	Prostatic Artery Embolization Versus 532 nm Green Light PVP for Catheterized Patients	Unknown status	NCT02006303	Phase 4
11	Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients	Unknown status	NCT01736033	Phase 4	Tamsulosin;Finasteride;Placebo
12	Metformin And Longevity	Unknown status	NCT02511665	Phase 4	Metformin;Placebo
13	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy	Unknown status	NCT01379742	Phase 4
14	Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada	Unknown status	NCT00573586	Phase 4
15	FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer	Unknown status	NCT00293670	Phase 4	Goserelin (Zoladex)
16	Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency	Unknown status	NCT02293759	Phase 4
17	Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications	Unknown status	NCT01876836	Phase 4
18	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer	Unknown status	NCT00906269	Phase 4	Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
19	Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)	Unknown status	NCT00922506	Phase 4	doxazosin plus tolterodine SR
20	MR-Lymphography and Lymph Node Staging in Prostate Cancer	Unknown status	NCT00185029	Phase 4
21	Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study	Completed	NCT00575913	Phase 4	Alfuzosin
22	Treatment of Chronic Bacterial Prostatitis	Completed	NCT02130713	Phase 4	Third generation fluoroquinolone
23	Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement	Completed	NCT00648323	Phase 4	Doxazosin mysylate GITS
24	Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years	Completed	NCT02757963	Phase 4
25	A Trial Assessing Peri-procedure Chemoprophylaxis During Transrectal Prostate Needle Biopsy	Completed	NCT02423759	Phase 4	ciprofloxacin;ciprofloxacin and gentamycine;culture based chemoprophylaxis
26	FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia	Completed	NCT02244255	Phase 4	FLOMAX® capsules;Ascending doses of HYTRIN® capsules
27	Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia	Completed	NCT02244242	Phase 4	Tamsulosin hydrochloride
28	Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients	Completed	NCT02244229	Phase 4	Tamsulosin;Finasteride;Placebo
29	KTP Green Light Prostatectomy Compared With Open Prostatectomy	Completed	NCT02072499	Phase 4
30	Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration	Completed	NCT02041767	Phase 4	Ertapenem
31	Prospective Sexual Function Study for BPH Subjects	Completed	NCT01777269	Phase 4	Dutasteride plus tamsulosin;Placebo
32	Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia	Completed	NCT01757769	Phase 4	Silodosin
33	Addition of Lidocaine to Levobupivacaine Reduces Intrathecal Block Duration	Completed	NCT01675895	Phase 4	Levobupivacaine lidocaine spinal anesthesia;levobupivacaine Spinal anesthesia
34	Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)	Completed	NCT01604811	Phase 4	Permixon® 160 mg;Tamsulosine Arrow LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine Arrow LP
35	Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia	Completed	NCT01500057	Phase 4
36	Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP)	Completed	NCT01494337	Phase 4
37	Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)	Completed	NCT01259531	Phase 4	Silodosin
38	Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate	Completed	NCT00880672	Phase 4	dutasteride
39	Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia	Completed	NCT00701779	Phase 4	Tamsulosin
40	Once Daily Given Alfuzosin in the Treatment of BPH	Completed	NCT00637715	Phase 4	Alfuzosin
41	SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin	Completed	NCT00486785	Phase 4	Alfuzosin
42	A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization	Completed	NCT00465101	Phase 4
43	Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study	Completed	NCT00427882	Phase 4	ALFUZOSIN
44	Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin	Completed	NCT00401661	Phase 4	Alfuzosin
45	A Prospective Evaluation of the GreenLight Model 120 Laser	Completed	NCT00364585	Phase 4
46	ALF-ONE : ALFuzosin ONcE Daily	Completed	NCT00280605	Phase 4	Alfuzosin
47	Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP)	Completed	NCT00199550	Phase 4
48	Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels	Completed	NCT00062790	Phase 4	Dutasteride
49	Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement	Completed	NCT01294592	Phase 4	Dutasteride plus tamsulosin;tamsulosin
50	Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction	Completed	NCT00827814	Phase 4	Dutasteride

Search NIH Clinical Center for Prostate Disease

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

mannitol hexanitrate

Cochrane evidence based reviews: prostatic diseases

Sources

Genetic Tests for Prostate Disease

Sources

Anatomical Context for Prostate Disease

MalaCards organs/tissues related to Prostate Disease:

⁴¹

Prostate, Bone, Testes, Lymph Node, Lung, T Cells, Kidney

Sources

Publications for Prostate Disease

Articles related to Prostate Disease:

(show top 50) (show all 179)

#	Title	Authors	Year
1	Setting up a service for men with benign prostate disease. ( 29561636 )	Firoz A.	2018
2	Canine Prostate Disease. ( 29933768 )	Christensen B.W.	2018
3	Association between male pattern baldness and prostate disease: A meta-analysis. ( 29054497 )	Jin T....Tang Y.	2018
4	Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. ( 29335762 )	Backhaus P....Rahbar K.	2018
5	Re: Evolution of Primary Care Referrals to Urology. Impact of a Protocol on Prostate Disease and Continuing Education. ( 29144897 )	Kaplan S.A.	2017
6	Dynamic instrumented palpation - a new method for soft tissue quality assessment: application to prostate disease diagnosis. ( 28965477 )	Yang T.J....McNeill S.A.	2017
7	Over-Expression of Activin-I^C Is Associated with Murine and Human Prostate Disease. ( 28116672 )	Ottley E.C....Gold E.	2017
8	Positive Response to Thermobalancing Therapy Enabled by Therapeutic Device in Men with Non-Malignant Prostate Diseases: BPH and Chronic Prostatitis. ( 28933398 )	Aghajanyan I.G....Allen S.	2016
9	Erratum: Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis. ( 27436144 )	Zhao J....Li L.	2016
10	Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis. ( 27170414 )	Zhao J....Li L.	2016
11	Re: Testosterone Replacement Therapy on the Natural History of Prostate Disease. ( 27845125 )	Kaplan S.A.	2016
12	Prostatectomy for benign prostate disease: open, laparoscopic and robotic techniques. ( 26497345 )	Ferretti M....Phillips J.	2015
13	The investigation of GSTP1, APC and RASSF1 gene promoter hypermethylation in urine DNA of prostate-diseased patients. ( 25665470 )	Haluskova J....Nagy V.	2015
14	Initial Evaluation of the Safety of Nanoshell-Directed Photothermal Therapy in the Treatment of Prostate Disease. ( 26296672 )	Stern J.M....Goodrich G.P.	2015
15	Testosterone Replacement Therapy on the Natural History of Prostate Disease. ( 26077355 )	Moore A....KAPhler T.S.	2015
16	Configuration and validation of a novel prostate disease nomogram predicting prostate biopsy outcome: A prospective study correlating clinical indicators among Filipino adult males with elevated PSA level. ( 29264129 )	Chua M.E....Luna S.L.	2015
17	Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases. ( 25323935 )	Akudugu J....BAPhm L.	2015
18	Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease. ( 26171936 )	Reis I.M....Singal R.	2015
19	MALDI MS profiling of post-DRE urine samples highlights the potential of I^-microseminoprotein as a marker for prostatic diseases. ( 24115268 )	Flatley B....Cramer R.	2014
20	Lycopene for the prevention and treatment of prostate disease. ( 24531784 )	Ilic D.	2014
21	Evolution of primary care referrals to urology. Impact of a protocol on prostate disease and continuing education. ( 25554605 )	SopeA+a-Sutil R....Passas-MartA-nez J.B.	2014
22	Serum amyloid A, phospholipase Aa88-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases. ( 24061501 )	Menschikowski M....Siegert G.	2013
23	Androgens and prostate disease. ( 24407178 )	Cooper L.A....Page S.T.	2013
24	Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications. ( 23690774 )	Murray N.P....DueA+as R.	2013
25	Effect of microbubble-enhanced ultrasound on prostate permeability: a potential therapeutic method for prostate disease. ( 23414693 )	Liu Y....Ye G.	2013
26	Current status of 5I+-reductase inhibitors in prostate disease management. ( 23614056 )	Kang D.I....Chung J.I.	2013
27	Seminal plasma glycoproteins in male infertility and prostate diseases: is there a chance for glyco-biomarkers? ( 23061682 )	Ferens-Sieczkowska M....Kratz E.M.	2013
28	Treatment for prostate disease should be uniform across the UK. ( 27794764 )	Davies K.	2012
29	Patient reported incontinence after radical prostatectomy is more common than expected and not associated with the nerve sparing technique: results from the Center for Prostate Disease Research (CPDR) database. ( 21826727 )	Peterson A.C....Chen Y.	2012
30	Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level &lt;10a88ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease? ( 22848218 )	Taverna G....Graziotti P.	2012
31	Prostate disease risk factors among a New Zealand cohort. ( 23363810 )	Karunasinghe N....Ferguson L.R.	2012
32	Botulinum toxin A in prostate disease: a venom from bench to bed-side. ( 22409179 )	Mearini L....Giannantoni A.	2012
33	Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-I+ and GPER signalling. ( 22233684 )	Williams G.	2012
34	Risk of prostate cancer associated with benign prostate disease: a primary care case-control study. ( 22054323 )	Buckley B.S....Sheikh A.	2011
35	The value of contrast-enhanced transrectal ultrasound in predicting the nature of prostate diseases and the Gleason score of prostate cancer by a subjective blood flow grading scale. ( 21832814 )	Zhao H.W....Chen W.	2011
36	Detecting gene-gene interactions in prostate disease in African American men. ( 21992608 )	Reams R.R....Yates C.	2011
37	Cholesterol and benign prostate disease. ( 21862201 )	Freeman M.R....Solomon K.R.	2011
38	Correlation between age and Chromogranin A determination in prostate diseases. ( 22674297 )	Mearini L....Porena M.	2011
39	Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. ( 21091976 )	Antonarakis E.S....McLeod D.G.	2011
40	Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. ( 21079217 )	Idan A....Handelsman D.J.	2010
41	N-glycosylation status of beta-haptoglobin in sera of patients with prostate cancer vs. benign prostate diseases. ( 19956848 )	Yoon S.J....Hakomori S.I.	2010
42	ACR appropriateness criteria on obstructive voiding symptoms secondary to prostate disease. ( 20362939 )	Dighe M....Sheth S.	2010
43	The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease. ( 20535861 )	Williams G.P.	2010
44	Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. ( 20647404 )	Gordian E....Singal R.	2010
45	A new vision for the study of benign prostate disease: the NIDDK Prostate Research Strategic Plan. ( 19150562 )	Mullins C....Kaplan S.A.	2009
46	Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. ( 19021204 )	Yasuda K....Fuse H.	2009
47	Clinical guidelines: should 5 alpha-reductase inhibitors be used for prostate disease? ( 19578352 )	Clarke N.W.	2009
48	A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits. ( 19267353 )	Montorsi F....Castro R.	2009
49	Evaluation of ischemia-modified albumin in myocardial infarction and prostatic diseases. ( 19375269 )	Mastella A.K....da Silva J.E.	2009
50	The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research. ( 19720304 )	Brassell S.A....McLeod D.	2009

Sources

Genes for Prostate Disease

Genes related to Prostate Disease (0 elite genes):

(show all 16)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	PCA3	Prostate Cancer Associated 3 Diagnostic marker Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	155.76	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵	21883822
2	H19	H19, Imprinted Maternally Expressed Transcript Putative susceptibility and diagnostic marker Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	150	Experimental evidence: Expression ³⁹	24373479
3	GAS5	Growth Arrest Specific 5 Tumour suppressor, putative oncogene host Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	150	Experimental evidence: Expression ³⁹	24373479
4	IGF2-AS	IGF2 Antisense RNA Association identified by GWAS. Dysfunction Pattern: Mutation	RNA Gene	150	Experimental evidence: Mutation ³⁹	19767753
5	CBR3-AS1	CBR3 Antisense RNA 1 Oncogene, putative therapeutic target Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	150	Experimental evidence: Expression ³⁹	24373479
6	PCAT1	Prostate Cancer Associated Transcript 1 They described PCAT1,a novel PCa lincRNA on 8q24,in the locality of well-characterized PCa risk-related SNPs and the c-MYC oncogene. Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	150	Experimental evidence: Expression ³⁹	24531795
7	CDKN2B-AS1	CDKN2B Antisense RNA 1 ANRIL is an antisense lncRNA elevated in PCa that overlaps this locus,interacting directly with polycomb repressive complex 1 and histone H3K27 methylation to repress CDKN2A-CDKN2B expression Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	150	Experimental evidence: Expression ³⁹	24721780
8	PTENP1	Phosphatase And Tensin Homolog Pseudogene 1 Oncogene, tumour suppressor Dysfunction Pattern: Expression [differentially expressed]	Pseudogene	150	Experimental evidence: Expression ³⁹	24373479
9	TERC	Telomerase RNA Component TERC is expressed in all human tissues regardless of telomerase activity,whereas TERT is highly expressed in >90% of tumor cells Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	150	Experimental evidence: Expression ³⁹	24146262
10	SCHLAP1	SWI/SNF Complex Antagonist Associated With Prostate Cancer 1 Prensner et al found that the lncRNA SChLAP1 was overexpresed in prostate tumors and where it is critical for tumor cell metastasis. Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	150	Experimental evidence: Expression ³⁹	24829860
11	PRNCR1	Prostate Cancer Associated Non-Coding RNA 1 Here we report that two lncRNAs highly overexpressed in aggressive prostate cancer,PRNCR1 (also known as PCAT8) and PCGEM1,bind successively to the androgen receptor and strongly enhance both ligand-dependent and ligand-independent androgen-receptor-mediated gene activation programs and proliferation in prostate cancer cells. Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	150	Experimental evidence: Expression ³⁹	24373479
12	CTBP1-AS	CTBP1 Antisense RNA Oncogene Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	150	Experimental evidence: Expression ³⁹	24373479
13	PCGEM1	PCGEM1, Prostate-Specific Transcript One of the earliest lncRNAs described in PCa,was PCGEM1(prostate cancer gene expression marker 1),a prostate-specific transcript encoded on 2q32 (40). One of the earliest lncRNAs described in PCa,was PCGEM1 (prostate cancer gene expression marker 1),a prostate-specific transcript encoded on 2q32 (40). Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	150	Experimental evidence: Expression ³⁹	24713835
14	MEG3	Maternally Expressed 3 MEG3 expression is lost. Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	150	Experimental evidence: Expression ³⁹	14602737
15	LINC00963	Long Intergenic Non-Protein Coding RNA 963 Linc00963: a novel,long non-coding RNA involved in the transition of prostate cancer from androgen-dependence to androgen-independence. Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	150	Experimental evidence: Expression ³⁹	24691949
16	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1 Putative marker Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	150	Experimental evidence: Expression ³⁹	22996375

Sources

Variations for Prostate Disease

Sources

Expression for Prostate Disease

Search GEO for disease gene expression data for Prostate Disease.

Sources

Pathways for Prostate Disease

Sources

GO Terms for Prostate Disease

Sources

Sources for Prostate Disease

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Prostate Disease

Aliases & Classifications for Prostate Disease

MalaCards integrated aliases for Prostate Disease:

Classifications:

External Ids:

Summaries for Prostate Disease

Related Diseases for Prostate Disease

Diseases related to Prostate Disease via text searches within MalaCards or GeneCards Suite gene sharing:

Comorbidity relations with Prostate Disease via Phenotypic Disease Network (PDN):

Graphical network of the top 20 diseases related to Prostate Disease:

Symptoms & Phenotypes for Prostate Disease

UMLS symptoms related to Prostate Disease:

Drugs & Therapeutics for Prostate Disease

Drugs for Prostate Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cochrane evidence based reviews: prostatic diseases

Genetic Tests for Prostate Disease

Anatomical Context for Prostate Disease

MalaCards organs/tissues related to Prostate Disease:

Publications for Prostate Disease

Articles related to Prostate Disease:

Genes for Prostate Disease

Genes related to Prostate Disease (0 elite genes):

Variations for Prostate Disease

Expression for Prostate Disease

Pathways for Prostate Disease

GO Terms for Prostate Disease

Sources for Prostate Disease

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :